10:01 AM EST - Cardiol Therapeutics Inc : Announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture, on Monday, November 18, at the American Heart Association Scientific Sessions 2024. Cardiol Therapeutics Inc
shares T.CRDL are trading up $0.09 at $2.77.
